Can a woman with fatty liver get pregnant? For most women, the answer is yes — fatty liver disease does not make pregnancy impossible. However, non-alcoholic fatty liver disease (NAFLD) is closely linked to insulin resistance, obesity, and polycystic ovary syndrome (PCOS), all of which can affect fertility and pregnancy outcomes. Understanding how NAFLD interacts with reproductive health, what risks to monitor during pregnancy, and how to optimise health before conception is essential for women and their clinicians. This article outlines the evidence, NHS preconception guidance, and when specialist referral is warranted.

Fatty Liver Disease and Female Fertility: What the Evidence Shows

Most women with fatty liver disease can conceive, but NAFLD's association with insulin resistance and PCOS can disrupt ovulation; advanced liver disease or cirrhosis poses greater fertility challenges.

Fatty liver disease, particularly non-alcoholic fatty liver disease (NAFLD), is increasingly common in women of reproductive age. A question many women and their clinicians face is whether this condition affects the ability to conceive. The short answer is that most women with fatty liver disease can become pregnant, but the condition may influence fertility and pregnancy outcomes in ways that are important to understand.

NAFLD is closely associated with metabolic syndrome — a cluster of conditions including insulin resistance, obesity, and dyslipidaemia — all of which can independently impair fertility. Evidence indicates that women with NAFLD have higher rates of polycystic ovary syndrome (PCOS), a leading cause of anovulatory infertility in the UK (NICE CKS: Polycystic ovary syndrome). The metabolic disturbances underpinning NAFLD can disrupt the hypothalamic-pituitary-ovarian (HPO) axis, contributing to irregular menstrual cycles and reduced ovulation frequency, though the relationship is associative rather than directly causal.

Fatty liver disease alone does not render a woman infertile. Many women with mild to moderate NAFLD conceive naturally without difficulty. The degree of liver fibrosis, the presence of associated metabolic conditions, and overall health status are all relevant factors. Women with more advanced liver disease — such as cirrhosis — may face greater challenges, as significant liver dysfunction can alter the metabolism of reproductive hormones including oestrogen and progesterone. Early identification and management of fatty liver disease is therefore beneficial for women planning a pregnancy (NICE NG49: Non-alcoholic fatty liver disease: assessment and management; NHS: Non-alcoholic fatty liver disease).

How Non-Alcoholic Fatty Liver Disease Affects Reproductive Health

NAFLD impairs reproductive health primarily through insulin resistance, which drives excess androgen production and suppresses ovulation — a mechanism closely linked to PCOS.

NAFLD affects reproductive health through several interconnected mechanisms. At its core, the condition is driven by insulin resistance, which causes excess fat to accumulate in liver cells (hepatocytes). This metabolic dysfunction has downstream effects on hormonal regulation that are particularly relevant to female fertility.

Insulin resistance promotes elevated levels of circulating insulin, which in turn stimulates the ovaries to produce excess androgens (male hormones). This hormonal imbalance is a hallmark of PCOS and can suppress normal ovulation. Studies estimate that up to 70–80% of women with PCOS have some degree of insulin resistance, and NAFLD is found in a significant proportion of women with PCOS — particularly those who are overweight or obese (NICE CKS: Polycystic ovary syndrome). The relationship is bidirectional and associative: metabolic dysfunction and PCOS appear to worsen each other, though causality is not fully established.

Some research has explored whether NAFLD-related systemic inflammation may affect the uterine environment, with chronic low-grade inflammation, elevated pro-inflammatory cytokines (such as TNF-α and IL-6), and oxidative stress all being features of NAFLD. However, direct evidence that these factors impair endometrial receptivity in humans remains limited, and this area requires further study before firm conclusions can be drawn.

Obesity — a major risk factor for NAFLD — is independently associated with reduced fertility, increased miscarriage rates, and poorer outcomes in assisted reproduction. Women with NAFLD who are also obese may therefore face compounded challenges. Addressing the underlying metabolic drivers of NAFLD — through dietary change, physical activity, and where appropriate, medical intervention — can meaningfully improve hormonal balance and reproductive potential.

Risks During Pregnancy for Women With Fatty Liver Disease

Women with NAFLD face increased risks of gestational diabetes, pre-eclampsia, preterm birth, and large-for-gestational-age infants; acute fatty liver of pregnancy is a rare but life-threatening emergency.

For women who do conceive with pre-existing fatty liver disease, it is important to be aware of the potential risks associated with pregnancy. Evidence suggests that NAFLD is linked to a higher likelihood of certain obstetric complications, though many women with well-managed fatty liver disease have uncomplicated pregnancies.

Key risks identified in the literature include:

• Gestational diabetes mellitus (GDM): Women with NAFLD are at significantly increased risk of developing GDM, given the shared pathophysiology of insulin resistance. GDM requires careful monitoring and management to protect both mother and baby (NHS: Gestational diabetes; NICE NG3: Diabetes in pregnancy).

• Pre-eclampsia: Evidence suggests an association between NAFLD and hypertensive disorders of pregnancy, including pre-eclampsia, which can have serious consequences if undetected (NICE NG133: Hypertension in pregnancy).

• Preterm birth: Metabolic disturbances associated with NAFLD may increase the risk of preterm delivery.

• Large-for-gestational-age (LGA) infant or macrosomia: Rather than fetal growth restriction, current evidence more consistently associates NAFLD and its metabolic comorbidities with increased birth weight and LGA infants, particularly where GDM is present.

• Increased risk of caesarean section and postpartum haemorrhage: Some studies report higher rates of operative delivery and postpartum haemorrhage in women with NAFLD and associated metabolic conditions.

• Acute fatty liver of pregnancy (AFLP): This is a rare but life-threatening condition distinct from pre-existing NAFLD. It typically presents in the third trimester with symptoms including nausea, vomiting, abdominal pain, and jaundice. Suspected AFLP requires immediate hospital assessment and is a medical emergency (RCOG guidance on acute fatty liver of pregnancy).

It is worth noting that normal pregnancy physiology causes changes in liver blood tests: alkaline phosphatase (ALP) rises (largely from placental origin), albumin falls due to haemodilution, and bilirubin may be slightly lower. ALT and AST do not typically rise in uncomplicated pregnancy, so any elevation warrants investigation. Women with advanced fibrosis or cirrhosis face additional risks, including complications of portal hypertension. Close monitoring by a multidisciplinary team is essential throughout pregnancy in these cases.

Preconception Advice and Medical Assessment on the NHS

Women with NAFLD planning pregnancy should see their GP for preconception assessment including liver function tests, ELF testing, metabolic screening, and medication review before conception.

Women with known fatty liver disease who are planning a pregnancy are strongly encouraged to seek preconception advice from their GP. This is an opportunity to optimise health before conception, reduce modifiable risk factors, and ensure that any necessary investigations or specialist referrals are in place.

A preconception assessment for a woman with NAFLD would typically include:

• Liver function tests (LFTs): To assess the current state of liver health and identify any active inflammation or dysfunction.

• Liver ultrasound: To detect hepatic steatosis and identify signs of advanced liver disease or alternative pathology. Ultrasound cannot reliably stage liver fibrosis.

• Enhanced Liver Fibrosis (ELF) test: NICE NG49 recommends the ELF test as the first-line non-invasive assessment for advanced fibrosis in adults with NAFLD in primary and secondary care. Liver elastography (such as FibroScan) may be used in secondary care pathways. The FIB-4 score is widely used in clinical practice but is not currently endorsed by NICE NG49 as a first-line tool, and its validity during pregnancy has not been established.

• Metabolic screening: Including fasting glucose, HbA1c, lipid profile, and BMI assessment.

• Screening for other causes of liver disease: Including viral hepatitis (hepatitis B and C serology) and a review of alcohol history, to exclude alternative or additional aetiologies.

• Vaccination review: Women should be offered hepatitis B vaccination if not immune, in line with NHS and UKHSA guidance.

• Review of medications: Several medications commonly used in the management of metabolic conditions require review or discontinuation before conception:

• Statins should generally be stopped when planning pregnancy, as they are contraindicated in pregnancy (MHRA guidance; individual SmPCs).
• GLP-1 receptor agonists (e.g., semaglutide, liraglutide) must be discontinued before conception; a washout period is recommended (refer to individual SmPCs and MHRA guidance).
• SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) should be stopped before pregnancy (MHRA/SmPC guidance).
• Other medications should be reviewed on an individual basis with the prescribing clinician.

NICE NG49 recommends a structured approach to lifestyle intervention as the cornerstone of NAFLD management. GPs can refer women to dietetic services and weight management programmes, and where appropriate, to specialist hepatology or obstetric medicine clinics. Women should also ensure they are taking folic acid before conception: 400 micrograms daily for most women, or 5 mg daily for those at higher risk — including women with a BMI of 30 or above, diabetes, those taking antiepileptic medicines, or those with a personal or family history of neural tube defects (NHS: Vitamins, supplements and nutrition in pregnancy).

Managing Fatty Liver Before and During Pregnancy

Lifestyle modification — particularly a Mediterranean-style diet and regular physical activity — is the primary treatment for NAFLD before and during pregnancy, as no licensed pharmacological therapy currently exists.

The management of fatty liver disease in the context of pregnancy planning centres on lifestyle modification and metabolic optimisation. There is currently no licensed pharmacological treatment specifically for NAFLD in the UK, making lifestyle intervention the primary therapeutic strategy — and one that is both safe and effective in the preconception period.

Dietary changes are fundamental. A Mediterranean-style diet — rich in vegetables, legumes, whole grains, oily fish, and olive oil, and low in ultra-processed foods, refined sugars, and saturated fats — has the strongest evidence base for reducing hepatic fat and improving metabolic markers. Reducing caloric intake to achieve even modest weight loss (5–10% of body weight) has been shown to significantly reduce liver fat and improve liver enzyme levels. Women who are pregnant or planning to conceive should avoid supplements containing vitamin A (retinol), as high doses can be harmful to a developing baby.

Physical activity plays an equally important role. Both aerobic exercise and resistance training have been shown to reduce hepatic steatosis independently of weight loss. NHS guidance recommends at least 150 minutes of moderate-intensity activity per week for adults; this level of activity is generally considered safe to continue during pregnancy, though women should seek individual advice from their midwife or GP (NHS: Exercise in pregnancy).

Alcohol should be avoided entirely when trying to conceive and throughout pregnancy. The UK Chief Medical Officers advise that there is no known safe level of alcohol in pregnancy.

Blood sugar management is particularly important for women with insulin resistance or type 2 diabetes. Metformin may be continued under specialist supervision in women with type 2 diabetes or PCOS who are planning pregnancy or are pregnant, in line with NICE NG3 (Diabetes in pregnancy). However, if metformin was prescribed solely for PCOS-related metabolic management rather than glycaemic control, its continuation should be reviewed individually with the prescribing clinician.

During pregnancy, women with fatty liver disease should attend all routine antenatal appointments and be screened for gestational diabetes at 24–28 weeks, or earlier if risk factors are present (NHS: Gestational diabetes). Women should be vigilant for symptoms of liver decompensation — including jaundice, severe nausea and vomiting, right upper quadrant pain, or confusion — and report any new or worsening symptoms promptly to their midwife or GP.

When to Seek Specialist Support From a Hepatologist or Obstetrician

Referral to a hepatologist is recommended for advanced fibrosis, cirrhosis, or persistently elevated liver enzymes; obstetric medicine input is needed for advanced liver disease, poorly controlled metabolic conditions, or acute liver symptoms in pregnancy.

While many women with mild NAFLD can be managed in primary care, certain clinical scenarios warrant prompt referral to a specialist. Understanding when to escalate care is an important aspect of patient safety for women with fatty liver disease who are pregnant or planning to conceive.

Referral to a hepatologist is recommended in the following situations:

• Evidence of advanced fibrosis on ELF test or liver elastography (FibroScan), or persistently elevated liver enzymes despite lifestyle intervention

• Suspected or confirmed cirrhosis

• History of liver-related complications such as ascites, variceal bleeding, or hepatic encephalopathy

• Uncertainty about the underlying cause of liver disease

• Women with cirrhosis or portal hypertension should be offered preconception assessment including consideration of endoscopic screening for oesophageal varices, in line with specialist hepatology practice (NICE QS152: Cirrhosis in over 16s)

Referral to a maternal medicine or obstetric medicine team should be considered for women with:

• Advanced liver disease or cirrhosis entering pregnancy

• A history of pre-eclampsia or gestational diabetes in a previous pregnancy

• Poorly controlled metabolic conditions (e.g., type 2 diabetes or severe obesity)

• Symptoms during pregnancy suggestive of acute liver dysfunction, including jaundice, severe nausea and vomiting, right upper quadrant pain, or confusion — these require immediate hospital assessment

Where fetal wellbeing is a concern, referral to a fetal medicine unit may also be appropriate.

Women should be encouraged to contact their GP or midwife promptly if they experience any of these warning symptoms during pregnancy. Acute fatty liver of pregnancy, though rare, is a medical emergency requiring urgent hospital admission (RCOG guidance on acute fatty liver of pregnancy).

A collaborative, multidisciplinary approach — involving the GP, hepatologist, obstetric medicine team, dietitian, and diabetes team where relevant — offers the best outcomes for women with fatty liver disease navigating pregnancy. With appropriate support and monitoring, many women with NAFLD go on to have healthy pregnancies and babies.

Frequently Asked Questions